CJC1295 (No DAC) + Ipamorelin (5 mg + 5 mg)

Overview

CJC-1295 is a synthetic peptide analogue of growth hormone releasing hormone (GHRH) that has been widely studied in endocrine and peptide research. The peptide was originally developed to investigate mechanisms that regulate growth hormone signaling and endocrine communication within the hypothalamic–pituitary axis.

CJC-1295 is designed to interact with GHRH receptors in the pituitary gland, which are involved in the natural signaling pathways responsible for regulating growth hormone release. Because of its structural stability and extended activity profile, the peptide has become an important compound in laboratory research exploring hormonal signaling and peptide-based endocrine modulation.

Researchers continue to study CJC-1295 for its potential role in growth hormone pathway signaling, metabolic regulation research, and cellular communication processes.

Research Areas of Interest

Growth Hormone Signaling Research

CJC-1295 has primarily been studied for its interaction with GHRH receptors, which are involved in the biological regulation of growth hormone secretion.

Experimental research focuses on how this peptide may influence signaling pathways within the hypothalamic–pituitary endocrine system, and how these pathways affect downstream cellular communication processes.

Endocrine System Research

Scientists have explored CJC-1295 in studies examining hormonal regulation mechanisms and endocrine feedback loops. These investigations help researchers better understand how peptide-based signaling molecules interact with complex hormonal systems in the body.

Metabolic and Cellular Regulation Studies

Research has also examined the role of CJC-1295 in metabolic communication pathways, including how endocrine signaling peptides may influence cellular activity, energy regulation, and tissue signaling processes in experimental models.

Peptide Stability and Pharmacokinetic Research

CJC-1295 has been studied extensively for its enhanced stability and prolonged activity compared with earlier GHRH analogues. Scientists continue to investigate how modifications to peptide structures influence receptor binding, signaling duration, and biological stability.

Ongoing Areas of Investigation

Current research involving CJC-1295 includes studies related to:

• growth hormone releasing hormone (GHRH) receptor signaling

• endocrine system communication

• metabolic pathway research

• peptide stability and pharmacokinetics

• hypothalamic–pituitary axis regulation

These areas remain active fields of investigation in peptide and endocrine research.

Product Information

• Compound: CJC-1295

• Class: GHRH analogue peptide

• Form: Lyophilized peptide powder

• Grade: Research grade

• Storage: Refrigerate at 2–8°C before reconstitution

• Use: Laboratory research only